Isolation and characterization of monoclonal antibodies against human carbonic anhydrase-IX

References

• Zatovicova M, Sedlakova O, Svastova E, Ohradanova A, Ciampor F, Arribas J, Pastorek J, Pastorekova S. 2005. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer. 93(11):1267–20. doi:10.1038/sj.bjc.6602861.
   PubMed Web of Science ®Google Scholar
• Thiry A, Supuran CT, Masereel B, Dogne JM. 2008. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 51(11):3051–56. doi:10.1021/jm701526d.
   PubMed Web of Science ®Google Scholar
• Thiry A, Dogne JM, Masereel B, Supuran CT. 2006. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci. 27(11):566–73. doi:10.1016/j.tips.2006.09.002.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Parkkila S, Pastorek J, Supuran CT. 2004. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem. 19(3):199–229. doi:10.1080/14756360410001689540.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. 2011. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 10(10):767–77. doi:10.1038/nrd3554.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Alterio V, Di Fiore A, Carta F, Monti SM, et al. 2018. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev. 38:1799–836.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Parkkila S, Parkkila AK, Opavsky R, Zelnik V, Saarnio J, Pastorek J. 1997. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology. 112(2):398–408. doi:10.1053/gast.1997.v112.pm9024293.
   PubMed Web of Science ®Google Scholar
• Saarnio J, Parkkila S, Parkkila AK, Waheed A, Casey MC, Zhou XY, Pastoreková S, Pastorek J, Karttunen T, Haukipuro K, et al. 1998. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J Histochem Cytochem. 46(4):497–504. doi:10.1177/002215549804600409.
   PubMed Web of Science ®Google Scholar
• Zavada J, Zavadova Z, Pastorek J, Biesova Z, Jezek J, Velek J. 2000. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer. 82(11):1808–13. doi:10.1054/bjoc.2000.1111.
   PubMed Web of Science ®Google Scholar
• Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, Parkkila S, Scaloni A, Pastorek J, Pastorekova S, and Pedone C. 2009. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci U S A. 106(38):16233–38. doi:10.1073/pnas.0908301106.
   PubMed Web of Science ®Google Scholar
• Mahon BP, Pinard MA, McKenna R. 2015. Targeting carbonic anhydrase IX activity and expression. Molecules. 20(2):2323–48. doi:10.3390/molecules20022323.
   PubMed Web of Science ®Google Scholar
• Buanne P, Renzone G, Monteleone F, Vitale M, Monti SM, Sandomenico A, Garbi C, Montanaro D, Accardo M, Troncone G, et al. 2013. Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells. J Proteome Res. 12(1):282–92. doi:10.1021/pr300565w.
   PubMed Web of Science ®Google Scholar
• Swayampakula M, McDonald PC, Vallejo M, Coyaud E, Chafe SC, Westerback A, Venkateswaran G, Shankar J, Gao G, Laurent EMN, et al. 2017. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene. 36(45):6244–61. doi:10.1038/onc.2017.219.
   PubMed Web of Science ®Google Scholar
• Opavsky R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada J, Kettmann R, Pastorek J. 1996. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics. 33(3):480–87. doi:10.1006/geno.1996.0223.
   PubMed Web of Science ®Google Scholar
• Innocenti A, Pastorekova S, Pastorek J, Scozzafava A, De Simone G, Supuran CT. 2009. The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors. Bioorg Med Chem Lett. 19(20):5825–28. doi:10.1016/j.bmcl.2009.08.088.
   PubMed Web of Science ®Google Scholar
• Ames S, Pastorekova S, Becker HM. 2018. The proteoglycan-like domain of carbonic anhydrase IX mediates non-catalytic facilitation of lactate transport in cancer cells. Oncotarget. 9(46):27940–57. doi:10.18632/oncotarget.25371.
   PubMedGoogle Scholar
• Jamali S, Klier M, Ames S, Barros LF, McKenna R, Deitmer JW, Becker HM. 2015. Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function. Sci Rep. 5(1):13605. doi:10.1038/srep13605.
   PubMedGoogle Scholar
• Andreucci E, Peppicelli S, Carta F, Brisotto G, Biscontin E, Ruzzolini J, Bianchini F, Biagioni A, Supuran CT, Calorini L, et al. 2017. Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med (Berl). 95(12):1341–53. doi:10.1007/s00109-017-1590-9.
   PubMed Web of Science ®Google Scholar
• Ihnatko R, Kubes M, Takacova M, Sedlakova O, Sedlak J, Pastorek J, KOPACEK J, and PASTOREKOVA S, et al. 2006. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. INTERNATIONAL JOURNAL OF ONCOLOGY. 29:1025–33.
   PubMed Web of Science ®Google Scholar
• Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E. 2013. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 14(6):11402–23. doi:10.3390/ijms140611402.
   PubMed Web of Science ®Google Scholar
• Supuran CT. 2008. Carbonic Anhydrases An Overview. Current Pharmaceutical Design. 14(7):603–14. doi:10.2174/138161208783877884.
   PubMed Web of Science ®Google Scholar
• Supuran CT. 2018. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opinion on Investigational Drugs. 27(12):963–70. doi:10.1080/13543784.2018.1548608.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, Lou Y, Vullo D, Scozzafava A, Dedhar S, Supuran CT. 2011. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem. 54(6):1896–902. doi:10.1021/jm101541x.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chia S, Bedard PL, Chu Q, Lyle M, Tang L, Singh M, Zhang Z, Supuran CT, Renouf DJ, et al. 2020. A Phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol. 43(7):484–90. doi:10.1097/COC.0000000000000691.
   PubMed Web of Science ®Google Scholar
• Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, and Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer . 1993;54:268-274.
   PubMed Web of Science ®Google Scholar
• Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Ekj P, Jonas U, Zwartendijk J, and Warnaar, SO. 1986. Monoclonal antibody G250 recognizes a determinant normal kidney present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 38.
   Web of Science ®Google Scholar
• Zatovicova M, Jelenska L, Hulikova A, Csaderova L, Ditte Z, Ditte P, Goliasova T, Pastorek J, Pastorekova S. 2010. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des. 16(29):3255–63. doi:10.2174/138161210793429832.
   PubMed Web of Science ®Google Scholar
• Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM. 1996. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol. 19(3):184–91. doi:10.1097/00002371-199605000-00003.
   PubMed Web of Science ®Google Scholar
• Chamie K, Donin NM, Klopfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, et al. 2017. Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. JAMA Oncol. 3(7):913–20. doi:10.1001/jamaoncol.2016.4419.
   PubMed Web of Science ®Google Scholar
• Basaco T, Pektor S, Bermudez JM, Meneses N, Heller M, Galvan JA, Boligán K, Schürch S, Von Gunten S, Türler A, et al. 2018. Evaluation of radiolabeled girentuximab in vitro and in vivo. Pharmaceuticals (Basel). 11(4):132. doi:10.3390/ph11040132.
   Google Scholar
• Xu C, Lo A, Yammanuru A, Tallarico AS, Brady K, Murakami A, Barteneva N, Zhu Q, Marasco WA, et al. 2010. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One. 5(3):e9625. doi:10.1371/journal.pone.0009625.
   PubMed Web of Science ®Google Scholar
• Petrul HM, Schatz CA, Kopitz CC, Adnane L, McCabe TJ, Trail P, Ha S, Chang YS, Voznesensky A, Ranges G, et al. 2012. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 11(2):340–49. doi:10.1158/1535-7163.MCT-11-0523.
   PubMed Web of Science ®Google Scholar
• Ebert T, Bander NH, Finstad CL, Ramsawak RD, Old LJ. 1990. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res. 50:5531–36.
   PubMed Web of Science ®Google Scholar
• Sheff JGKJ, Robotham A, Sulea T, Malenfant F, L’Abbé D, Duchesne M, Pelletier A, Lefebvre J, Acel A, et al. 2021. HDX-MS reveals three unique binding responses of mAbs to the catalytic domain of hCAIX. MAbs. in press.
   PubMed Web of Science ®Google Scholar
• Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM. 2002. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother. 51(3):171–77. doi:10.1007/s00262-002-0268-4.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf Dem Keller U, Leung S, Huntsman D, et al. 2011. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 71(9):3364–76. doi:10.1158/0008-5472.CAN-10-4261.
   PubMed Web of Science ®Google Scholar
• Brown WS, McDonald PC, Nemirovsky O, Awrey S, Chafe SC, Schaeffer DF, Li J, Renouf DJ, Stanger BZ, Dedhar S, et al. 2020. Overcoming adaptive resistance to KRAS and MEK inhibitors by Co-targeting mTORC1/2 complexes in pancreatic cancer. Cell Rep Med. 1(8):100131. doi:10.1016/j.xcrm.2020.100131.
   PubMedGoogle Scholar
• McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, et al. 2019. Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia. Gastroenterology. 157(3):823–37. doi:10.1053/j.gastro.2019.05.004.
   PubMed Web of Science ®Google Scholar
• Pandit-Taskar N, Postow MA. 2020. Immune-directed molecular imaging biomarkers. Semin Nucl Med. 50(6):584–603. doi:10.1053/j.semnuclmed.2020.06.005.
   PubMed Web of Science ®Google Scholar
• Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inoges S, Melero I, Berraondo P. 2017. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol. 95(4):347–55. doi:10.1038/icb.2017.6.
   PubMed Web of Science ®Google Scholar
• Davis ID, Liu Z, Saunders W, Lee FT, Spirkoska V, Hopkins W, et al. 2007. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun. 7:14.
   PubMedGoogle Scholar
• Lawrentschuk N, Lee FT, Jones G, Rigopoulos A, Mountain A, O’Keefe G, Papenfuss AT, Bolton DM, Davis ID, Scott AM, et al. 2011. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (1)(2)(4) I-cG250PET/CT. Urol Oncol. 29(4):411–20. doi:10.1016/j.urolonc.2009.03.028.
   PubMed Web of Science ®Google Scholar
• Zatovicova M, Jelenska L, Hulikova A, Ditte P, Ditte Z, Csaderova L, Svastova E, Schmalix W, Boettger V, Bevan P, et al. 2014. Monoclonal antibody G250 targeting CA: binding specificity, internalization and therapeutic effects in a non-renal cancer model. Int J Oncol. 45(6):2455–67. doi:10.3892/ijo.2014.2658.
   PubMed Web of Science ®Google Scholar
• Antal I, Koneracka M, Kubovcikova M, Zavisova V, Jurikova A, Khmara I, Omastova M, Micusik M, Barathova M, Jelenska L, et al. 2021. Targeting of carbonic anhydrase IX-positive cancer cells by glycine-coated superparamagnetic nanoparticles. Colloids Surf B Biointerfaces. 205:111893. doi:10.1016/j.colsurfb.2021.111893.
   PubMed Web of Science ®Google Scholar
• Chen M, Hu J, Wang L, Li Y, Zhu C, Chen C, Shi M, Ju Z, Cao X, Zhang Z, et al. 2020. Targeted and redox-responsive drug delivery systems based on carbonic anhydrase IX-decorated mesoporous silica nanoparticles for cancer therapy. Sci Rep. 10(1):14447. doi:10.1038/s41598-020-71071-1.
   PubMed Web of Science ®Google Scholar
• Krall N, Pretto F, Decurtins W, Bernardes GJ, Supuran CT, Neri D. 2014. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl. 53(16):4231–35. doi:10.1002/anie.201310709.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Ziffels B, Widmayer F, Murer P, Pellegrini G, Pretto F, Wulhfard S, Neri D. 2018. Enhanced Therapeutic activity of non-internalizing small-molecule-drug conjugates targeting carbonic anhydrase IX in combination with targeted interleukin-2. Clin Cancer Res. 24(15):3656–67. doi:10.1158/1078-0432.CCR-17-3457.
   PubMed Web of Science ®Google Scholar
• Millul J, Krudewig C, Zana A, Dakhel Plaza S, Puca E, Villa A, Neri D, Cazzamalli S. 2021. Immunotherapy with Immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX. Mol Cancer Ther. 20(3):512–22. doi:10.1158/1535-7163.MCT-20-0361.
   PubMed Web of Science ®Google Scholar
• Indira Chandran V, Mansson AS, Barbachowska M, Cerezo-Magana M, Nodin B, Joshi B, Koppada N, Saad OM, Gluz O, Isaksson K, et al. 2020. Hypoxia attenuates trastuzumab uptake and Trastuzumab-Emtansine (T-DM1) cytotoxicity through redistribution of phosphorylated caveolin-1. Mol Cancer Res. 18(4):644–56. doi:10.1158/1541-7786.MCR-19-0856.
   PubMed Web of Science ®Google Scholar
• Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, et al. 2015. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol. 35(Suppl):S199–S223.
   PubMedGoogle Scholar
• Murri-Plesko MT, Hulikova A, Oosterwijk E, Scott AM, Zortea A, Harris AL, Ritter G, Old L, Bauer S, Swietach P, et al. 2011. Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. Eur J Pharmacol. 657(1–3):173–83. doi:10.1016/j.ejphar.2011.01.063.
   PubMed Web of Science ®Google Scholar
• Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM, Boswell A. 2010. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS One. 5(5):e10857. doi:10.1371/journal.pone.0010857.
   PubMed Web of Science ®Google Scholar
• Lau J, Lin K-S, Benard F. 2017. past, present, and future: development of theranostic agents targeting carbonic anhydrase IX. Theranostics. 7(17):4322–39. doi:10.7150/thno.21848.
   PubMed Web of Science ®Google Scholar
• Supuran CT. 2016. Structure and function of carbonic anhydrases. Biochem J. 473(14):2023–32. doi:10.1042/BCJ20160115.
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouysségur J. 2009. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 69(1):358–68. doi:10.1158/0008-5472.CAN-08-2470.
   PubMed Web of Science ®Google Scholar
• Doyen J, Parks SK, Marcie S, Pouyssegur J, Chiche J. 2012. Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis. Front Oncol. 2:199.
   PubMedGoogle Scholar
• Lock FE, McDonald PC, Lou Y, Serrano I, Chafe SC, Ostlund C, Aparicio S, Winum J-Y, Supuran CT, Dedhar S, et al. 2013. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 32(44):5210–19. doi:10.1038/onc.2012.550.
   PubMed Web of Science ®Google Scholar
• Durocher Y, Butler M. 2009. Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol. 20(6):700–07. doi:10.1016/j.copbio.2009.10.008.
   PubMed Web of Science ®Google Scholar
• Durocher Y, Perret S, Kamen A. 2002. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30(2):E9. doi:10.1093/nar/30.2.e9.
   PubMed Web of Science ®Google Scholar
• Tom R, Bisson L, Durocher Y. 2008. Purification of his-tagged proteins using fractogel-cobalt. CSH Protoc. 2008:pdb prot4980.
   Google Scholar
• Wilbur KM, Andrson NG. 1948. Electrometric and colorimetric determination of carbonic anhydrase. J Biol Chem. 176(1):147–54. doi:10.1016/S0021-9258(18)51011-5.
   PubMed Web of Science ®Google Scholar
• Chafe SC, McDonald PC, Saberi S, Nemirovsky O, Venkateswaran G, Burugu S, Gao D, Delaidelli A, Kyle AH, Baker JHE, et al. 2019. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol Res. 7(7):1064–78. doi:10.1158/2326-6066.CIR-18-0657.
   PubMed Web of Science ®Google Scholar
• Brown WS, McDonald PC, Nemirovsky O, Awrey S, Chafe SC, Schaeffer DF, et al. 2020. Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1/2 complexes in pancreatic cancer. Cell Rep Med. 1.
   Google Scholar
• Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G. 2018. TumGrowth: an open-access web tool for the statistical analysis of tumor growth curves. Oncoimmunology. 7(9):e1462431. doi:10.1080/2162402X.2018.1462431.
   PubMed Web of Science ®Google Scholar